Navigation Links
Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
Date:12/2/2008

VANCOUVER, Dec. 2 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced the initiation of a clinical trial of the Company's RAMP(R) test to detect Respiratory Syncytial Virus (RSV). Prospective data from the clinical study is expected to be used to support a submission to the U.S. Food and Drug Administration (FDA) and other regulatory jurisdictions for market clearance of the 3M Rapid Detection RSV test for clinical use. The study is designed to demonstrate the performance characteristics of the RSV test versus standard laboratory culture and Direct Fluorescence Staining Assay (DFSA) for RSV using multiple sample types. The study is a multi-centre prospective clinical study to be conducted in North America at approximately eight clinical sites.

"We are excited to commence this clinical trial, which is the second clinical indication in infectious diseases developed for 3M Health Care," said S. Wayne Kay, Chief Executive Officer. "RSV is a very common disease that affects most children in their first two years of life. RSV is also common in the elderly and is often confused with influenza. There remains a significant clinical need for a rapid test that provides high clinical sensitivity for RSV compared to viral culture or DFSA."

The successful development of this test would allow physicians to quickly diagnose the presence or absence of RSV virus and optimize the clinical management of the RSV positive patient. A highly sensitive and rapid RSV test would allow more effective management of large RSV outbreaks and reduce the amount of unnecessary antibiotic administrations.

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in
'/>"/>

SOURCE Response Biomedical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy
2. FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
3. Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governors Plea to Help the States Population in Need
4. Zimbabwean Health Workers Call For Crisis Response
5. TV News Story on Canine Cancer Generates Dog Lover Response - No. 1 Health Issue for Americas 40 Million Dog-Owning Households
6. iMedExchange Responses to Financial Crisis
7. Response rates to antidepressants differ among English- and Spanish-speaking Hispanics
8. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
9. Response Biomedical Closes $5.1 Million Financing
10. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
11. Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...
(Date:5/21/2013)... 21, 2013 HealthSmart continues to grow ... presence has required the hiring of new talent in ... pleased to announce that Dawn Powell has joined the ... the Director of Account Management in the Central Region ... Irving, Texas. With extensive client management, employee benefits, and ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... Tips on What to Do Now as States Struggle,with ... Red Cross,chapters throughout the Midwest are keeping pace with ... landscape, despite several,chapter offices being closed due to the ... from home or using partnerships with,local government or community ...
... 11 AIDS Healthcare,Foundation (AHF) today blasted former ... for his stubbornness and,recent failure to apologize for ... in which he called for people living with,HIV/AIDS ... the time, Huckabee,told Associated Press in response to ...
... Sell Out Consumers with Unaffordable Mandate, SANTA MONICA, ... as much as 14% have led a state panel,to ... health plans. The vote,came less than a month before ... or pay penalties that increase monthly, and as,California politicians ...
... Calls on Every Candidate from Every Party to ... WASHINGTON, Dec. 11 AIDS Action released a,statement ... rewrite,his HIV/AIDS platform to ensure that the policies ... and end stigma against people,living with HIV. "Governor ...
... new study in Nature, Brandeis University Howard Hughes Medical ... curtain on the secret lives of enzymes, the ubiquitous ... a slew of sophisticated technologies to capture a key ... able to show that these proteins are not the ...
... bortezomib (Velcade) and two other drugs is showing a ... multiple myeloma, a team headed by Dana-Farber Cancer Institute ... Society of Hematology. , The three-pronged regimen of Velcade, ... has achieved an overall response rate of 98 ...
Cached Medicine News:Health News:Darkness and Cold Prevail in the Midwest 2Health News:Darkness and Cold Prevail in the Midwest 3Health News:Darkness and Cold Prevail in the Midwest 4Health News:Huckabee's Defense of Earlier, Alarmist AIDS Stance Shows Unsuitability for Presidency, Says AHF 2Health News:Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed 2Health News:AIDS Action Calls on Huckabee to Follow HIV/AIDS Science 2Health News:Caught in the act: The dynamic dance of enzymes 2Health News:3-drug combination 'extremely promising' as first-line therapy for multiple myeloma 2
(Date:5/21/2013)... 2013 BioElectronics Corp. (PINKSHEETS: BIEL), the ... announced that CEO, Andrew J. Whelan ... Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling ... the counter sales. "It,s been 37 ... classification schema," Whelan said.  "While the old classification ...
(Date:5/21/2013)... 2013  Janssen R&D Ireland (Janssen) today announced ... Phase 3 PROMISE study demonstrating that use of ... sustained virologic response 12 weeks after the end ... genotype 1 chronic hepatitis C adult patients with ... fibrosis, when administered once daily with pegylated interferon ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... Novocure, a commercial stage private oncology company, announced ... supply agreement with ITT Electronic Systems, a subsidiary ... (NYSE: ITT). ITT Electronic Systems supplies Novocure with ... disposable electrodes for the NovoTTF-100A System, an FDA ...
... American Pacific Corporation (NASDAQ: APFC ... its Fiscal 2011 third quarter financial results on Thursday, August ... and Chief Executive Officer and Dana Kelley, Vice President, Chief ... at 1:30 p.m. Pacific Time. Callers may listen ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3American Pacific to Release Financial Results and Hold Fiscal 2011 Third Quarter Investor Teleconference 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: